Search results for " prospective"

showing 10 items of 244 documents

Phytosterol plasma concentrations and coronary heart disease in the prospective Spanish EPIC cohort

2010

Phytosterol intake with natural foods, a measure of healthy dietary choices, increases plasma levels, but increased plasma phytosterols are believed to be a coronary heart disease (CHD) risk factor. To address this paradox, we evaluated baseline risk factors, phytosterol intake, and plasma noncholesterol sterol levels in participants of a case control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) Spanish cohort who developed CHD (n = 299) and matched controls (n = 584) who remained free of CHD after a 10 year follow-up. Sitosterol-to-cholesterol ratios increased across tertiles of phytosterol intake (P = 0.026). HDL-cholesterol level increased, …

AdultMalecampesterolmedicine.medical_specialtyCampesterolPopulationCoronary DiseaseLathosterolQD415-436lathosterolBiochemistryplant sterolsCohort Studieschemistry.chemical_compoundEndocrinologyRisk FactorsInternal medicineHumansMedicineProspective StudiesRisk factoreducationProspective cohort studyAgededucation.field_of_studyCholesterolbusiness.industrycholesterolPhytosterolsCell BiologyEuropean Prospective Investigation into Cancer and NutritionMiddle AgedDietEuropean Prospective Investigation into Cancer and NutritionEndocrinologysitosterolchemistrySpainCase-Control StudiesNested case-control studyFemalelipids (amino acids peptides and proteins)Patient-Oriented and Epidemiological ResearchbusinessJournal of Lipid Research
researchProduct

Palliative Sedation in Patients With Advanced Cancer Followed at Home: A Prospective Study

2014

Abstract Context Home care programs in Italy. Objectives The aim of this study was to assess a protocol for palliative sedation (PS) performed at home. Methods A total of 219 patients were prospectively assessed to evaluate a PS protocol in patients with advanced cancer followed at home by two home care programs with different territorial facilities. The protocol was based on stepwise administration of midazolam. Results A total of 176 of the patients died at home, and PS was performed in 24 of these patients (13.6%). Younger patients received the procedure more frequently than older patients (P = 0.012). The principal reasons to start PS were agitated delirium (n = 20) and dyspnea (n = 4).…

AdultMaleend of lifemedicine.medical_specialtyPalliative careContext (language use)Settore MED/42 - Igiene Generale E ApplicataPalliative sedationend of life; midazolam; palliative care; Palliative sedation; Adult; Aged; Aged 80 and over; Delirium; Dyspnea; Family; Feasibility Studies; Female; Humans; Hypnotics and Sedatives; Italy; Male; Midazolam; Middle Aged; Neoplasms; Palliative Care; Patient Care Team; Prospective Studies; Terminal Care; Young Adult; Home Care Services; Anesthesiology and Pain Medicine; Neurology (clinical); Nursing (all)2901 Nursing (miscellaneous); Medicine (all)Young AdultPalliative sedationNeoplasms80 and overmedicineHumansHypnotics and SedativesFamilyIn patientProspective StudiesIntensive care medicineProspective cohort studyNursing (all)2901 Nursing (miscellaneous)General NursingAgedAged 80 and overPatient Care TeamTerminal Carepalliative carebusiness.industryMedicine (all)DeliriumMiddle AgedHome Care ServicesAdvanced cancerDistressDyspneaAnesthesiology and Pain MedicinePalliative sedation; end of life; midazolam; palliative careItalymidazolamEmergency medicineFeasibility StudiesMidazolamFemaleNeurology (clinical)businessmedicine.drugJournal of Pain and Symptom Management
researchProduct

Advancement flap in the management of chronic anal fissure: A prospective study

2012

Lateral internal sphincterotomy is the surgical treatment of choice of chronic anal fissure after failure of conservative measures. Several randomized trials identified an overall risk of incontinence of 10 % mostly for flatus. Fissurectomy is the most commonly used procedure to preserve the integrity of the anal sphincters. However, a possible complication is keyhole defect that may lead to faecal soiling. In this study, chronic anal fissure (CAF) was treated by fissurectomy and anal advancement flap to preserve the anatomo-functional integrity of sphincters and to reduce healing time and the risk of anal stenosis. In patients with hypertonia, surgical treatment was combined with chemical …

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentInjections IntramuscularSurgical FlapsFissurectomyFollow-Up StudieInternal anal sphincterAnal stenosismedicineDeformityHumansReconstructive Surgical ProcedureProspective StudiesKeyhole defectBotulinum Toxins Type ADigestive System Surgical ProceduresAdvancement flapAgedNeuromuscular Agentbusiness.industryUrinary retentionDigestive System Surgical ProcedureRecovery of FunctionPlastic Surgery ProceduresMiddle AgedSurgerySurgical FlapProspective StudieSettore MED/18 - Chirurgia GeneraleTreatment OutcomeNeuromuscular AgentsAnesthesiaChronic DiseaseDefecationHypertoniaFemaleSurgeryFissure in AnoAdvancement flap; Chronic anal fissure; Fissurectomy; Adolescent; Adult; Aged; Botulinum Toxins Type A; Chronic Disease; Digestive System Surgical Procedures; Female; Fissure in Ano; Follow-Up Studies; Humans; Injections Intramuscular; Male; Middle Aged; Neuromuscular Agents; Prospective Studies; Reconstructive Surgical Procedures; Recovery of Function; Treatment Outcome; Surgical Flaps; Surgerymedicine.symptombusinessLateral internal sphincterotomyChronic anal fissureFollow-Up StudiesHuman
researchProduct

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observation…

2014

Importance The evaluation of therapeutic choices is needed after 24 doses of natalizumab in patients with multiple sclerosis (MS). Objective To evaluate the effect of therapeutic choices on the mean annualized relapse rate and on magnetic resonance imaging MS activity after 24 doses of natalizumab in patients with relapsing-remitting MS. Design, Setting, and Participants The TY-STOP study, which recruited participants between October 22, 2010, and October 22, 2012, at 8 Italian MS centers (secondary care outpatient clinics) among 124 adult patients who demonstrated no clinical or magnetic resonance imaging MS activity after 24 doses of natalizumab. Interventions Natalizumab, no treatment, i…

AdultMalemedicine.medical_specialtyAdult; Antibodies Monoclonal Humanized; Humans; Italy; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Natalizumab; Prospective Studies; Recurrence; Treatment OutcomeAntibodies Monoclonal HumanizedNatalizumabMultiple Sclerosis Relapsing-RemittingRecurrenceInternal medicineClinical endpointmedicineOutpatient clinicHumansProspective StudiesGlatiramer acetateMultiple Sclerosis Ty-STOP Natalizumabbusiness.industryProgressive multifocal leukoencephalopathyNatalizumabMiddle Agedmedicine.diseaseFingolimodMagnetic Resonance ImagingSurgeryDiscontinuationClinical trialTreatment OutcomeItalySettore MED/26 - NeurologiaNeurology (clinical)businessmedicine.drugJAMA neurology
researchProduct

Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomograp…

2009

Abstract Purpose In the pre—positron emission tomography era, the Gruppo Italiano Studio Linfomi (GISL) investigated the feasibility and efficacy of a treatment based on a response-tailored number of doxorubicin/bleomycin/vinblastine/dacarbazine (ABVD) courses in 218 intermediate-stage Hodgkin lymphoma patients. Patients and Methods Patients with stage I/II showing at least one adverse prognostic factor and stage IIIA without adverse prognostic factors were recruited. Treatment included a first step of 3 ABVD courses, followed by an early-restaging. Patients in CR/CRu received 1 additional ABVD cycle, patients in PR received 3 more ABVD, and nonresponder patients went off study. Involved-fi…

AdultMalemedicine.medical_specialtyCancer ResearchAdolescentDacarbazinemedicine.medical_treatmentEarly restagingVinblastineBleomycinYoung AdultAdolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; Doxorubicin; Female; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Vinblastine; Young AdultAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProspective StudiesStage (cooking)Prospective cohort studyAgedNeoplasm StagingChemotherapyAntineoplastic Combined Chemotherapy Protocolmedicine.diagnostic_testbusiness.industryGeneral MedicineHematologyMiddle AgedCombined Modality TherapyHodgkin DiseaseSurgeryVinblastineRadiation therapyDacarbazineProspective StudieABVDOncologyDoxorubicinErythrocyte sedimentation ratePositron-Emission TomographyFemaleRadiologybusinessmedicine.drugHumanClinical lymphomamyeloma
researchProduct

Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma

2015

OBJECTIVES:The Barcelona Clinic Liver Cancer (BCLC) intermediate stage (BCLC B) includes a heterogeneous population of patients with hepatocellular carcinoma (HCC). Recently, in order to facilitate treatment decisions, a panel of experts proposed to subclassify BCLC B patients. In this study, we aimed to assess the prognostic capability of the BCLC B stage reclassification in a large cohort of patients with untreated HCC managed by the Italian Liver Cancer Group.METHODS:We assessed the prognosis of 269 untreated HCC patients observed in the period 1987-2012 who were reclassified according to the proposed subclassification of the BCLC B stage from stage B1 to stage B4. We evaluated and compa…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularPrognosiAdult; Aged; Aged 80 and over; Carcinoma Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Young Adult; GastroenterologyGastroenterologyIntermediate stage03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicinemedicineCarcinoma80 and overHumansProspective StudiesProspective cohort studyAgedNeoplasm StagingAged 80 and overHepatologybusiness.industryMedicine (all)Settore MED/09 - MEDICINA INTERNACarcinomaLiver NeoplasmsGastroenterologyHepatocellularMiddle Agedmedicine.diseasePrognosisProspective StudieLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyNeoplasm stagingFemaleLiver cancerbusinessHuman
researchProduct

Impact of Tips Preliver Transplantation for the Outcome Posttransplantation

2008

The effects of transjugular intrahepatic portocaval shunt (TIPS) on the survival of grafts and patients after liver transplantation (LTx) have only been documented in small series and with only a comparative description with non-TIPS recipients. We evaluated 61 TIPS patients who had a subsequent LTx and compared these with 591 patients transplanted with cirrhosis without TIPS. Pretransplant characteristics were similar between groups. Graft survival at 1, 3 and 5 years post-LTx was 85.2%, 77% and 72.1% (TIPS) and 75.3%, 69.8% and 66.1% (controls). Patient survival at the same points was 91.7%, 85% and 81.7%, respectively (TIPS) and 85.4%, 80.3% and 76.2% (controls). Cox regression showed th…

AdultMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentLiver transplantationlaw.inventionPostoperative ComplicationslawmedicineTransjugular IntrahepaticHumansImmunology and AllergyPharmacology (medical)Prospective StudiesPortasystemic ShuntSurvival analysisTransplantationbusiness.industryProportional hazards modelLiver transplantation portal hypertension TIPSStentMiddle Agedmedicine.diseaseAdult; Female; Humans; Male; Middle Aged; Postoperative Complications; Prospective Studies; Survival Analysis; Liver Transplantation; Portasystemic Shunt Transjugular Intrahepatic; Treatment OutcomeSurvival AnalysisIntensive care unitLiver TransplantationSurgeryTransplantationTreatment OutcomePortal hypertensionFemalePortasystemic Shunt Transjugular IntrahepaticbusinessAmerican Journal of Transplantation
researchProduct

Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study

2016

Background and Aims: Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nested case-control study, we aimed to characterise incident cases of cancer in IBD. The role of immunomodulators vs clinical characteristics of IBD as risk factors for cancer was also investigated. Materials and Methods: From January 2012 to December 2014, each IBD patient with incident cancer was matched with two IBD patients without cancer for: IBD type, gender, and age. Risk factors were assessed by multivariate regression analysis. Results: IBD patients considered numbered 44619: 21953 Crohn’s disease \[CD], 22666 ulcerative colitis [UC]. Cancer occurred in 174 patients…

AdultMalemedicine.medical_specialtyPancolitisAdolescentColorectal cancerphenotypeSettore MED/12 - GASTROENTEROLOGIAcancer riskInflammatory bowel disease; cancer risk; phenotype; Adolescent; Adult; Aged; Aged 80 and over; Case-Control Studies; Female; Follow-Up Studies; Humans; Immunologic Factors; Incidence; Inflammatory Bowel Diseases; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasms; Prospective Studies; Risk Factors; Young Adult; PhenotypeGastroenterologyInflammatory bowel diseaseInflammatory bowel disease03 medical and health sciencesYoung Adult0302 clinical medicineRisk FactorsInternal medicineNeoplasms80 and overmedicineHumansImmunologic FactorsProspective StudiesRisk factorProspective cohort studyAgedAged 80 and overbusiness.industryIncidenceSettore MED/09 - MEDICINA INTERNAGastroenterologyCancerGeneral MedicineMiddle Agedmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisLogistic Models030220 oncology & carcinogenesisCase-Control StudiesNested case-control studyMultivariate Analysis030211 gastroenterology & hepatologyFemalemedicine.symptombusinessInflammatory bowel disease; cancer risk; phenotypeFollow-Up Studies
researchProduct

Oral self-injuries: clinical findings in a series of 19 patients

2015

Objectives: Self-injury (SI) is defined as a behavioral disturbance consisting of a deliberate harm to one’s own body without suicidal intent, it is not uncommon and ranges in severity from simple nail-biting to more extreme forms of self-mutilation. The head neck region may be the target of such lesions. SI is associated with several medical conditions, of which it can represent the first clinical sign. Aim of this paper is to describe a series of oral SI, giving special emphasis to the clinical findings, etiology and the management of lesions. Material and Methods: A total of 19 patients with oral SI were prospectively examined; attention was paid to the occurrence and characterization of…

AdultMalemedicine.medical_specialtyPediatricsAdolescentPoison controlOdontologíaDiseaseLesionYoung AdultInjury preventionmedicineHumansMedical historyAdolescent; Adult; Aged; Aged 80 and over; Child; Female; Humans; Male; Middle Aged; Mouth; Prospective Studies; Wounds and Injuries; Young Adult; Self-Injurious BehaviorProspective StudiesYoung adultProspective cohort studyChildGeneral DentistryAgedAged 80 and overMouthOral Medicine and Pathologybusiness.industryResearchWounds and InjurieMiddle Aged:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludSurgeryProspective StudieOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASEtiologyWounds and InjuriesSurgeryFemalemedicine.symptombusinessSelf-Injurious BehaviorHuman
researchProduct

Immune tolerance induction with moroctocog-alpha (Refacto/Refacto AF) in a population of Italian haemophilia A patients with high-titre inhibitors: D…

2019

Background: The appearance of inhibitors is the most serious complication in haemophilia A (HA) patients. The primary objective is their eradication. Up to date, immune tolerance induction (ITI) was the only therapeutic option to achieve this. Aim: To assess the efficacy of moroctocog-alpha as an ITI regimen in a population of HA patients with high-titre inhibitors. Methods: The REF.IT Registry is a retrospective-prospective study that collected data on all patients with HA and high-titre inhibitors treated with moroctocog-alpha as an ITI regimen at twelve Italian Haemophilia Centres. Results: We enrolled 27 patients, 85.2% were children. All patients were high responders, 88.9% had severe …

AdultMalemedicine.medical_specialtyPopulationHaemophilia AAlpha (ethology)030204 cardiovascular system & hematologyHaemophiliaHemophilia Ahaemophilia A with inhibitors; immune tolerance induction; moroctocog-alpha; poor-prognosis ITI patients; Adult; Child; Child Preschool; Factor VIII; Female; Hemophilia A; Humans; Immune Tolerance; Italy; Male; Prospective Studies; Retrospective Studies; Risk Factors; RegistriesImmune tolerance03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineImmune ToleranceMedicineHumansProspective StudiesRegistrieseducationHigh titrePreschoolChildGenetics (clinical)Retrospective Studiesimmune tolerance inductioneducation.field_of_studyFactor VIIIbusiness.industryHematologyGeneral Medicinehaemophilia A with inhibitormedicine.diseasepoor-prognosis ITI patientsRegimenItalymoroctocog-alphaChild PreschoolFemalebusinessComplicationhaemophilia A with inhibitors030215 immunologyHaemophilia : the official journal of the World Federation of HemophiliaREFERENCES
researchProduct